Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 61.43 CNY, compared to the current stock price of 54.92 CNY as of March 23, 2026 [5]. Core Insights - The company reported a revenue of 6.7 billion CNY for 2025, representing a year-on-year growth of 13.17%. After adjustments, the growth rate for 2024 was 8.83%. The net profit attributable to shareholders was 1.739 billion CNY, up 11.67% year-on-year, with a non-recurring net profit of 1.638 billion CNY, growing by 13.62% [1][2]. - The company has established a dual-driven business growth model combining pharmaceuticals and health consumer products, achieving significant growth in its core product lines, particularly in the health sector [2][3]. - The company aims to continue its high-quality development strategy during the 14th and 15th Five-Year Plans, focusing on innovation, product diversification, and integration of cultural and industrial strategies [3]. Financial Performance - In 2025, the company achieved a total profit of 2.06 billion CNY, with a net asset return rate of 16.7%, an increase of 2.1 percentage points. The operating cash ratio stood at 34.2%, indicating a strong cash flow position [1]. - The company has maintained a high dividend payout ratio, with cash dividends totaling 9.22 billion CNY for 2025, representing 100% of the net profit attributable to shareholders [10]. - Revenue growth is projected to continue at rates of 11.3%, 11.4%, and 11.5% for 2026, 2027, and 2028, respectively, with net profit growth rates of 13.8%, 13.6%, and 13.2% for the same years [11]. Business Segmentation - The revenue from the company's core product, Ejiao and its series, reached 6.198 billion CNY in 2025, growing by 11.80% year-on-year. Other pharmaceuticals and health products saw a remarkable increase of 63.65%, while revenue from donkey breeding and meat products declined by 15.53% [2]. - The company is focusing on expanding its product lines, including the development of new health products targeting male consumers and enhancing its presence in the health snack market [2]. Strategic Outlook - The company is committed to integrating into the national health development strategy, enhancing its dual-driven business model, and expanding its market influence through a comprehensive narrative system [3]. - Future growth strategies include investment and acquisitions to diversify product offerings and strengthen operational capabilities [3].

Macro Economic Overview - Industrial production remains resilient, with construction activity showing seasonal variation but overall acceptable performance. Recent weeks have seen a mixed construction start rate, with asphalt plant operation rates dropping to historical lows for the lunar period, while cement dispatch rates are at historical mid-high levels [3][4] - Demand for construction materials remains higher than the same lunar period in 2025, with a rebound in offline home appliance sales. Recent data indicates positive year-on-year demand for rebar and building materials, suggesting a potential bottoming out of construction demand [4] Commodity Prices - International commodity prices have been influenced by ongoing geopolitical tensions in the Middle East, with oil prices continuing to rise. Recent fluctuations in gold prices are attributed to short-term liquidity and sentiment factors, with a recommendation to buy on dips due to long-term bullish outlook [5] - Domestic industrial product prices are showing a strong upward trend, with energy prices rising and the South China industrial product index reflecting this strength [5] Real Estate Market - In first-tier cities, new housing transaction volumes are showing positive year-on-year growth. Recent data indicates a significant increase in transaction area in major cities compared to the same lunar period in previous years [6] - The second-hand housing market in cities like Beijing and Shanghai is performing well, with transaction volumes showing mixed year-on-year changes [6] Military Industry Insights - The military industry index has seen a significant decline of 10.70% over the past two weeks, underperforming compared to the broader market. The current price-to-earnings ratio for the military sector is at 74.13 times, indicating a high valuation relative to historical levels [9] - Geopolitical tensions are expected to accelerate military trade and sales, with recent developments in the Middle East suggesting a potential increase in military exports [10] Commercial Aerospace Developments - The commercial aerospace sector is experiencing significant activity, with new projects and collaborations emerging. Notable developments include the establishment of a joint venture for satellite design and manufacturing, and advancements in space computing technology [11] - Companies in the commercial aerospace sector are expected to benefit from ongoing capital and industry support, indicating a high level of industry vitality [11] Semiconductor Industry Analysis - The domestic wafer foundry industry is poised for growth, with local leaders expected to replicate the success of international counterparts. The current environment is favorable for profit recovery driven by downstream inventory replenishment and price increases [15][19] - The semiconductor industry is characterized by high capital and ecological barriers, with geopolitical factors and AI demand driving a restructuring of global manufacturing dynamics [18] AI and Gaming Sector Trends - Major companies are significantly increasing their investments in AI, with Tencent and Alibaba reporting substantial growth in AI-related revenues. Upcoming game releases are expected to enhance market engagement and revenue potential [21][22] - The gaming sector is anticipated to enter a new growth cycle with the launch of major titles, suggesting a favorable outlook for gaming companies amidst economic uncertainties [22] Automotive Service Sector - The automotive service platform, Tuhu, has reported steady revenue growth and is actively expanding its market presence. The company has become the largest independent automotive service platform globally, with plans for further international expansion [35][36] - Tuhu's proactive pricing strategy aims to attract more consumers, although profit growth may slow due to changing consumer preferences [35] Pharmaceutical Industry Updates - The pharmaceutical company, Kunming Pharmaceutical Group, is facing operational challenges but is focusing on growth in the elderly health sector. The company has adjusted its profit forecasts for the coming years, reflecting a cautious outlook [39] - Dong-E E-Jiao has reported improved operational efficiency and growth potential in the health supplement market, maintaining a positive investment rating [44]

Investment Rating - The report does not specify a clear investment rating for the company [1] Core Insights - The company achieved a revenue of 6.70 billion yuan in 2025, representing a year-on-year increase of 8.83%, and a net profit attributable to the parent company of 1.74 billion yuan, up 11.66% year-on-year [8] - The core business of "Ejiao and related products" generated revenue of 6.20 billion yuan, growing by 11.80% year-on-year, while the "other medicines and health products" segment saw a significant increase of 63.65% to 386 million yuan [8] - The company is expanding into new health segments through acquisitions, such as Inner Mongolia Alashan Cistanche Group and Dongfeng Maji Pharmaceutical [8] - The gross profit margin for 2025 was 73.47%, with a slight increase of 1.05 percentage points year-on-year [8] Financial Performance Summary - Revenue projections for 2026-2028 are 7.70 billion yuan, 8.79 billion yuan, and 9.83 billion yuan, with growth rates of 14.86%, 14.27%, and 11.75% respectively [3][12] - Net profit attributable to the parent company is expected to reach 2.20 billion yuan in 2026, 2.58 billion yuan in 2027, and 2.96 billion yuan in 2028, with corresponding growth rates of 26.25%, 17.30%, and 14.84% [3][12] - The company plans to maintain a high dividend payout, with a total cash return to shareholders of 1.82 billion yuan in 2025, representing 104.6% of the net profit [8] Business Segment Analysis - The pharmaceutical industrial segment is projected to generate revenue of 7.00 billion yuan in 2026, with a stable gross margin of 75% [11] - The "other medicines and health products" segment is expected to grow significantly, with revenue forecasts of 580 million yuan in 2026, 840 million yuan in 2027, and 1.09 billion yuan in 2028, maintaining a gross margin of 70% [11] - The donkey breeding and trading business is anticipated to decline, with revenue projections of 60 million yuan for 2026, remaining stable thereafter [11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company is expected to achieve revenue of 6.7 billion yuan in 2025, representing a year-on-year increase of 8.83%. The net profit attributable to shareholders is projected to be 1.739 billion yuan, up 11.66% [4] - The company maintains a strong focus on the health supplement sector, particularly in the ejiao category, and is optimistic about the long-term growth potential from its product diversification and industry chain layout [4] - The company plans to distribute a cash dividend of 14.31 yuan per 10 shares, totaling 922 million yuan, which reflects a commitment to high shareholder returns [6] Financial Performance Summary - In 2025, the company's revenue from ejiao and related products reached 6.198 billion yuan, an increase of 11.80%, with a gross margin of 74.84% [5] - The company’s operating profit for 2025 is projected at 2.071 billion yuan, with a net profit margin of 25.95% [4][8] - The earnings per share (EPS) for 2025 is estimated at 2.70 yuan, with future projections of 3.04 yuan for 2026 and 3.45 yuan for 2027 [8] Valuation Metrics - The current price-to-earnings (P/E) ratio is projected to be 18.5 for 2026, 16.2 for 2027, and 14.3 for 2028, indicating a favorable valuation trend [4][8] - The company has maintained a high dividend payout ratio, averaging around 70% over the years, which enhances shareholder confidence [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company is expected to achieve revenue of 6.7 billion yuan in 2025, representing a year-on-year increase of 8.83%. The net profit attributable to shareholders is projected to be 1.739 billion yuan, up 11.66% year-on-year. The company maintains a strong gross margin of 73.47% and a net margin of 25.95% [4][5] - The company has a robust dividend policy, distributing 14.31 yuan per 10 shares, totaling 922 million yuan, which accounts for 100% of the net profit attributable to shareholders for 2025. This reflects a commitment to providing high returns to shareholders [6] Financial Performance Summary - Revenue for 2025 is forecasted at 6.7 billion yuan, with a year-on-year growth of 8.83% [4] - The net profit attributable to shareholders is expected to be 1.739 billion yuan, reflecting an increase of 11.66% [4] - The gross margin is projected to be 73.47%, an increase of 1.05 percentage points, while the net margin is expected to be 25.95%, a decrease of 0.35 percentage points [4] - The company’s sales expense ratio is expected to decrease to 32.00%, while the management expense ratio is projected at 7.21% [4] - The earnings per share (EPS) for 2026, 2027, and 2028 are forecasted to be 3.04 yuan, 3.45 yuan, and 3.91 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 18.5, 16.2, and 14.3 [4][8] Revenue Breakdown - Revenue from the company's Aojiao and related products is expected to reach 6.198 billion yuan, a year-on-year increase of 11.80%, with a gross margin of 74.84% [5] - Other pharmaceutical and health products are projected to generate revenue of 386 million yuan, up 63.65% [5] - Revenue from donkey breeding and donkey meat products is expected to decline to 58 million yuan, down 15.53% [5] Dividend Policy - The company plans to distribute a cash dividend of 14.31 yuan per 10 shares, totaling 922 million yuan, which is 100% of the net profit attributable to shareholders for 2025 [6]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [4]. Core Insights - The company reported a revenue of 6.7 billion RMB for 2025, representing a year-on-year growth of 13.17%. The net profit attributable to shareholders was 1.739 billion RMB, up 11.67% year-on-year, indicating overall performance in line with expectations [1]. - The core product line, particularly the Ejiao series, shows strong resilience with a gross margin of 74.84%, slightly up by 1.23% year-on-year. The revenue from the pharmaceutical segment reached 6.584 billion RMB, growing by 13.91% [2]. - The company is investing 1.485 billion RMB in a health consumer goods industrial park, aiming to expand its product offerings in the health sector, which is expected to drive long-term growth [3]. Financial Performance Summary - For 2025, the company achieved a revenue of 6.7 billion RMB, with a net profit of 1.739 billion RMB, and a diluted earnings per share (EPS) of 2.700 RMB. The projected net profits for 2026, 2027, and 2028 are 1.994 billion RMB, 2.279 billion RMB, and 2.630 billion RMB, respectively, with corresponding EPS of 3.096 RMB, 3.538 RMB, and 4.085 RMB [4][10]. - The company plans to distribute a total cash dividend and share buyback amounting to approximately 1.819 billion RMB, which is 104.60% of the net profit for 2025, reflecting a strong commitment to shareholder returns [2].

Core Insights - The essence of the New Year gift boxes is shifting from traditional ceremonial consumption to a focus on intrinsic product value, as consumers demand more than just attractive packaging and compelling stories [2][4] - Brands must provide solid reasons for consumers to choose their products, leading to a competition that emphasizes product innovation and "hard currency" value [6] Product Innovation Trends - The first key transformation is the extreme precision of "functional value," where products must clearly address specific consumer needs, exemplified by Danone's targeted offerings for GLP-1 drug users [6][8] - The second transformation involves AI reconstructing flavor and experience, as seen in Genki Forest's use of AI for over 500 flavor iterations to enhance product appeal [8][10] - The third transformation is the modernization of "food as medicine," with brands like Dong'e Ejiao offering convenient, ready-to-eat products that fit modern lifestyles [10][12] - The fourth transformation focuses on "value traceability" in the supply chain, where brands with superior raw materials and quality control gain competitive advantage, as demonstrated by premium chocolate brands [12][14] Market Dynamics - The traditional marketing strategies are failing, necessitating a return to physical experiences to build consumer trust, as evidenced by the popularity of membership-based supermarkets like PDD and Sam's Club [14][15] - Successful brands are now prioritizing in-person experiences to establish trust and validate their products before mass production [15][16] Consensus Building - Brands are exploring efficient ways to validate their concepts, such as participating in industry exhibitions to gather feedback and insights from professionals [20][22] - The contrasting approaches of brands like Daily Black Chocolate and Zhongke Muzhen highlight the importance of consensus building before product launch, ensuring that products enter the market with validated consumer interest [22][23] Role of Industry Exhibitions - Industry exhibitions serve as critical platforms for brands to verify trends, calibrate value, and establish trust, enabling them to gather concentrated information and insights in a short time [26][28] - These events facilitate deep connections between brands and potential partners, significantly reducing risks associated with cross-border trade and enhancing supply chain capabilities [30]

Core Insights - The article discusses the evolving landscape of consumer behavior regarding traditional New Year gift boxes, highlighting a shift towards more rational purchasing decisions as consumers prioritize product value over packaging and marketing narratives [2][3]. Group 1: Shifts in Consumer Behavior - The essence of New Year gift boxes is rooted in ceremonial consumption, representing emotional, social, and cultural values, but consumers are increasingly questioning the intrinsic value of these products beyond their festive symbolism [3]. - Consumers are gravitating towards membership-based supermarkets like Pinduoduo and Sam's Club, indicating a preference for self-branded products that offer perceived value [2]. Group 2: Product Innovation Trends - Brands must provide compelling reasons for consumers to choose their products, leading to a focus on deep product innovation rather than superficial marketing [5]. - The first key transformation is the precise definition of "functional value," where products must clearly address specific consumer needs, exemplified by Danone's targeted offerings for GLP-1 drug users [5][6]. - The second transformation involves AI-driven flavor and experience reconstruction, as seen in Genki Forest's use of AI for over 500 flavor iterations to enhance product appeal [10]. - The third transformation is the modernization of "food as medicine," with brands like Dong'e Ejiao offering convenient, ready-to-eat products that fit contemporary lifestyles [12]. - The fourth transformation focuses on value sourcing from the supply chain, where brands that control high-quality raw materials and production processes gain a competitive edge [14]. Group 3: Market Trust and Experience - As product innovation becomes a necessity, brands face the challenge of gaining market visibility and trust in a fragmented information landscape [16]. - Successful brands are returning to physical spaces to create tangible experiences that foster consumer trust, as demonstrated by the popularity of membership stores [16]. - The concept of "consensus pre-sale" is emerging, where brands validate their products through community engagement or industry exhibitions before market launch, ensuring they enter the market with established consumer trust [25][26]. Group 4: The Role of Industry Exhibitions - Industry exhibitions serve as critical platforms for brands to validate trends, calibrate value, and build trust, allowing companies to quickly gather insights and feedback from industry peers and consumers [29]. - Exhibitions facilitate rapid trust-building through direct interactions, which are essential for establishing commercial partnerships and reducing risks in cross-border trade [33]. - New brands leverage exhibitions to connect with potential partners and streamline their innovation processes, enhancing their ability to bring products to market effectively [33].

Core Viewpoint - Dong-E E-Jiao has confirmed its absence from the current bull market, with a year-to-date decline of 18% as of December 22, 2025. The company needs to identify new growth points, such as E-Jiao paste, male products, and international expansion, to regain momentum [1][12][13]. Stock Performance - As of December 22, 2025, Dong-E E-Jiao's stock closed at 49.25 yuan, reflecting a total market capitalization of 31.72 billion yuan. The stock has seen an 18% decline since the beginning of the year, contrasting sharply with the overall A-share market, where over 4,300 stocks recorded positive gains [2][14]. - The company has initiated a share buyback plan, intending to use 100 million to 200 million yuan to repurchase shares at a maximum price of 72.08 yuan per share. This is expected to involve the repurchase of approximately 138,730 to 277,470 shares, representing 0.22% to 0.43% of the total share capital [2][15]. Dividend Policy - Dong-E E-Jiao plans to distribute a cash dividend of 12.69 yuan per 10 shares, totaling approximately 817 million yuan, which indicates a high payout ratio. From 2020 to 2024, the company has consistently maintained a high dividend payout ratio, with a total cash dividend of 1.96 billion yuan in 2020, increasing to 15.55 billion yuan in 2024 [3][15][16]. Historical Context - Dong-E E-Jiao was once regarded as the "Moutai of medicine," experiencing a long-term bull market. However, after a series of price increases that led to a disconnect between product pricing and consumer demand, the company faced significant challenges, including a net profit loss of 455 million yuan in 2019 [4][18]. - The leadership transition from Qin Yufeng to Gao Dengfeng in 2020 marked a shift in strategy, with a renewed focus on E-Jiao paste, which has seen significant sales growth due to favorable policy changes [6][19][20]. Recent Developments - The company has launched new products targeting male consumers, such as the "Royal Weichang 1619" brand, and has made strategic acquisitions in the male health supplement sector [9][22]. - Dong-E E-Jiao is also expanding its international presence, having acquired Huaren Pharmaceutical Trading (Hong Kong) Co., Ltd. and established partnerships in Southeast Asia, although overseas revenue remains a small portion of total income [10][24].

Core Viewpoint - The concept of "food and medicine sharing the same source" is gaining popularity, leading to increased demand for health products, particularly ready-to-eat Ejiao products, driven by various consumer demographics including the elderly, women, and Gen Z [1][8]. Market Overview - The ready-to-eat Ejiao market in China is projected to reach a scale of 54.3 billion yuan in 2024, representing a year-on-year growth of 22.3%, accounting for 25% of the overall ready-to-eat health product market [1][8]. - Ready-to-eat Ejiao is produced through optimized formulations and improved processes, making it convenient for modern lifestyles [2][3]. Market Policies - Recent policies emphasize food safety and quality control across all stages of production, processing, and distribution of ready-to-eat Ejiao, promoting a shift towards standardized and high-quality industry practices [4][5]. Industry Chain - The upstream of the ready-to-eat Ejiao industry includes suppliers of key raw materials such as donkey hide, black sesame, walnuts, red dates, honey, and rock sugar, while the midstream consists of production companies, and the downstream includes various sales channels [6][7]. Current Development - The demand for ready-to-eat Ejiao is expanding beyond traditional consumers to include working professionals and younger generations, with consumption scenarios evolving to include daily snacks and gift-giving [8][9]. Competitive Landscape - The ready-to-eat Ejiao market is characterized by a concentrated competitive structure, dominated by two major players, Dong'e Ejiao and Fupai Ejiao, which control key raw material supplies and have established strong brand loyalty [10]. - Dong'e Ejiao reported a revenue of 3.051 billion yuan in the first half of 2025, with 93.2% of this coming from Ejiao and related products [11]. - Fupai Ejiao achieved a revenue of 2.104 billion yuan in 2024, marking a 5% increase, with over 40% of sales coming from non-Ejiao block products [12]. Future Trends - The ready-to-eat Ejiao product line is expected to diversify further, introducing more portable and snack-like options, while also targeting specific consumer needs such as prenatal nutrition and weight management [13]. - The international market for ready-to-eat Ejiao is anticipated to expand, initially targeting regions with high Chinese populations and gradually moving towards Western markets [13].